Xience Prime time
This article was originally published in The Gray Sheet
Executive Summary
Abbott receives CE mark approval for the next-generation everolimus-eluting coronary stent, clearing the way for a European market launch in the third quarter, the firm says June 23. Xience Prime uses the same drug and biocompatible polymer as Abbott's market-leading Xience V stent, available in the U.S. and Europe, but has a novel design and modified delivery system for greater flexibility and improved deliverability, the company says (1"The Gray Sheet" July 7, 2008). Xience Prime will be available in a broad range of sizes, including Prime SV for small vessels and Prime LL for long lesions
You may also be interested in...
Research In Brief
Abbott DES Trial: Abbott announces start of SPIRIT PRIME, the U.S. clinical trial of its next-generation Xience Prime everolimus-eluting coronary stent, during its July 15 second-quarter earnings call. The company expects to launch Xience Prime in the U.S. in 2012. Abbott recently began shipping Xience Prime to select accounts in Europe following receipt of a CE Mark in June (1"The Gray Sheet" June 29, 2009). Xience Prime is available in a broad range of sizes up to 38 mm. SPIRIT PRIME is a 500-patient, 75-center nonrandomized trial with two arms. The core size arm will follow 400 patients treated with a stent from 2.25 mm to 4.0 mm in diameter and 8 mm to 28 mm in length, and the long lesion arm will follow 100 patients with a stent 2.5 mm to 4.0 mm in diameter and either 33 mm or 38 mm in length. The primary endpoint is major adverse cardiac events
Xience V / Promus Drug-Eluting Stent Is Off And Running On U.S. Market
Abbott remains confident that it will gain 25% to 30% share of the U.S. drug-eluting stent market over the next year now that it has launched its Xience V everolimus-eluting stent
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”